Piaoyang Sun, PhD.
Chairman of Jiangsu Hengrui Medicine Co., Ltd
Dr. Piaoyang Sun is Chairman of the Board of Jiangsu Hengrui Medicine Co., Ltd. Outside Hengrui, he also serves as adjunct professor at China Pharmaceutical University, member of the 8th, 9th and 10th Chinese Pharmacopoeia Commission, vice-chairman of Jiangsu Association for Science and Technology, vice-chairman of Jiangsu Federation of Industry and Commerce, and multiple other academic and social service positions.
Dr. Sun has decades of leadership experience in pharmaceutical R&D and management. As the founder and leader of Hengrui, he has led the company’s major drive towards innovation and globalization. Under his leadership, Hengrui’s team launched two Class 1.1 innovative drugs Imrecoxib and Apatinib in the past six years, and a number of innovative drug are now undergoing clinical studies in the US. Hengrui is currently leading in antibody drug conjugate (ADC), immunotherapy and multiple other categories/disease areas in China. In 2015, Hengrui successfully out-licensed its investigational anti-PD-1 monoclonal antibody to the US biotech company Incyte and in-licensed an antiemetic drug, rolapitant from Tesaro for China. In addition, in recent years, Hengrui has marketed multiple products including Injectables in the US and EU, making it the only Chinese pharmaceutical company attaining this achievement. His vision and focus on innovation and quality has not only transformed Hengrui, but also impacted and influenced the entire Chinese pharmaceutical industry.
Dr. Sun earned a bachelor’s degree in Medicinal Chemistry from China Pharmaceutical University and obtained his doctorate in Organic Chemistry from Nanjing University.
Lianshan Zhang, PhD.
Vice President of Jiangsu Hengrui Medicine
Dr. Lianshan Zhang holds the position of Vice President of Jiangsu Hengrui Medicine. Hengrui is widely recognized as the domestic leader in pharmaceutical R&D innovation in China. In 2010, Dr. Zhang joined Hengrui and takes the responsibility for R&D strategy and management of dozens of NMEs across the globe. Prior to Hengrui, he was a senior research executive at Marcadia Biotech, in charge of all the chemistry efforts and external research collaborations. From 1998 to 2008, Dr. Zhang was engaged in the discovery and development of peptide therapeutics for the treatment of diabetes and obesity and successfully delivered multiple clinical candidates.
Dr. Zhang received his undergraduate degree in Medicinal Chemistry from China Pharmaceutical University and his Ph.D. (summa cum laude) in Organic Chemistry at the University of Tubingen. He conducted his post-doctoral research at University of Tubingen and Vanderbilt University in the area of peptide and protein therapeutics.